Cognition, Metacognition, and Stigma in Patients With Suicidal Ideation
2 other identifiers
observational
220
0 countries
N/A
Brief Summary
Deficits of executive function, meta cognition and stigma is known in suicidal ideation; however, their relationship is unknown. Since many studies use a single indicator of executive function and, it was considered important to study. Metacognition, executive functioning and stigma are the possible driving force behind the suicidal behavior in human being. With respect to research in the Indian context, there is paucity of studies exploring these factors. The purpose of the present study is to explore the relationships between executive functioning, metacognition, and stigma in suicidal ideation and suicide attempters in the Indian setup, where there is a lacuna in research regarding the same. Having a detailed understanding of these psychological parameters will be helpful in suicide prevention and management.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2026
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 16, 2024
CompletedFirst Posted
Study publicly available on registry
October 22, 2024
CompletedStudy Start
First participant enrolled
December 1, 2026
ExpectedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2027
Study Completion
Last participant's last visit for all outcomes
March 31, 2028
March 27, 2026
March 1, 2026
1.1 years
October 16, 2024
March 23, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Metacognition measured by Metacognitions Questionnaire (MCQ-3) scores
The Metacognitions Questionnaire-30 (MCQ-30) is a self-report measure that assesses metacognitive beliefs. The MCQ-30 is comprised of five factors. Responses are required on a four-point scale ranging from 1 (do not agree) to 4 (agree very much), high scores reflect more reported problems with the item in question.
Within one week
Depression, Anxiety and Stress Scale-21 scores
Depression, Anxiety and Stress Scale-21 Items (DASS-21): The Depression, Anxiety and Stress Scale - 21 Items (DASS-21) is a set of three self-report scales designed to measure the emotional states of depression, anxiety and stress. The anxiety scale assesses autonomic arousal, skeletal muscle effects, situational anxiety, and subjective experience of anxious affect. The stress scale is sensitive to levels of chronic nonspecific arousal. It assesses difficulty relaxing, nervous arousal, and being easily upset / agitated, irritable / over-reactive and impatient. Scores for depression, anxiety and stress are calculated by summing the scores for the relevant items.Higher scores mean more anxiety or depression and low scores means low anxiety or depression.
Within one week
Stigma of Suicide Scale (SOSS) scores
The Stigma of Suicide Scale is designed to assess stigmatizing attitudes of general community members toward people who suicide. The short form consists of 16 items. Each item consists of a one-word descriptor of a person who dies by suicide. We will use the short form. Each item is to be rated on a 5-point Likert scale from (1) strongly disagree to (5) strongly agree. Higher scores indicate higher levels of stigma towards people who suicide.
Within one week
Study Arms (1)
Persons with suicide attempt or suicide ideation
Individuals with high suicide ideation or suicide attempts visiting ABVIMS -Dr. RML Hospital for treatment will be screened for this study.
Interventions
Individuals with high suicide ideation or suicide attempts visiting ABVIMS -Dr. RML Hospital for treatment will be screened for this study. socio- demographics details will also be gathered. Following this Depression, Anxiety and Stress Scale (DASS-21), Wisconsin Card Sorting Test (WCST), Metacognitions Scale (MCQ-30) and Stigma of Suicide Scale (SOSS) will be administered.
Eligibility Criteria
The present study is a cross sectional study. For the purpose of this study, individuals with suicidal ideation and attempts who are seeking treatment at the outpatient department of Psychiatry, as well as medical emergency of Dr. RML Hospital or referred to Department of Clinical Psychology would be approached to participate in the study.
You may qualify if:
- Any gender
- Age between 18 to 60 years.
- Able to read and write in Hindi and English
- With a primary mental health diagnosis of anxiety, depression, acute stress reaction or adjustment disorder, or with no diagnosis at all
- Persons with high suicidal ideation (Score 2 or more in first five items of BSSI)
- Person who attempted suicide in last three months.
You may not qualify if:
- Any comorbid personality disorder diagnosis
- Diagnosis of a major mental disorder such as Schizophrenia or Bipolar Affective Disorder.
- Intellectual Disability and neurological disorder.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Vishwajit L Nimgaonkar, MD, PhD
University of Pittburgh
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
October 16, 2024
First Posted
October 22, 2024
Study Start (Estimated)
December 1, 2026
Primary Completion (Estimated)
December 31, 2027
Study Completion (Estimated)
March 31, 2028
Last Updated
March 27, 2026
Record last verified: 2026-03
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF
- Time Frame
- After one year of publication of results of the study.
- Access Criteria
- Study should be ethically approved and scientifically sound.
De-identified individual participant data collected during the trial as well as protocol will be shared on request at 1-2 years after article publication.